Article Text

Download PDFPDF
No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis
  1. P Härle1,
  2. P Sarzi-Puttini2,
  3. M Cutolo3,
  4. R H Straub1
  1. 1Laboratory of Experimental Rheumatology and Neuroendocrino-Immunology, Department of Internal Medicine I, University Hospital, 93042 Regensburg, Germany
  2. 2Rheumatology Unit, University Hospital L Sacco, Milan, Italy
  3. 3Division of Rheumatology, Department of Internal Medicine and Medical Specialties, University of Genova, Italy
  1. Correspondence to:
    Professor R H Straub

Statistics from

Leptin and adiponectin, two fat tissue hormones, are increased or tend to be increased in patients with rheumatoid arthritis (RA).1,2 They are likely to be stimulated by proinflammatory cytokines such as tumour necrosis factor (TNF),3,4 and both were found to be increased in the synovial fluid of patients with RA.1,2 Thus, one would expect lowering of serum levels of these two hormones during anti-TNF antibody treatment.

As part of a recently published study with adalimumab (Abbott SpA, Campoverde di Aprilia, Italy),5 we included 32 white patients with RA (30 postmenopausal women, two men) fulfilling the American College of Rheumatology criteria for RA.6 The patients were selected according to the inclusion criteria of the adalimumab Research in Active RA study (ReAct). A total of 16 patients (15 female, one male) did not receive parallel or prior (6 months before) prednisolone treatment. The other 16 patients (15 female, one male) received prednisolone …

View Full Text


  • Conflict of interest: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.